Meteora Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Meteora Capital’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-300,000	Closed	-$12.1M	–	442
2026 Q1	$12.1M	Buy	+300,000	New	+$6.46M	0.89%	40

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Meteora Capital's APLS Position: Q2 2026 in Review

Meteora Capital sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 300,000 shares — an estimated $12.1M sold.

Meteora Capital first reported a position in APLS in Q1 2026 and held it in 1 quarter. The position peaked at $12.1M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Meteora Capital reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Meteora Capital sold 300,000 Apellis Pharmaceuticals shares in Q2 2026, an estimated $12.1M.
Meteora Capital first reported a position in Apellis Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Meteora Capital's Apellis Pharmaceuticals position peaked at $12.1M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Meteora Capital's 13F filing for Q2 2026, filed 14 Aug 2026.